(Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection ...
The rapid growth of generative artificial intelligence (GenAI) is creating a new digital divide in K–12 education, an AI skills gap that threatens to leave some students behind. While some schools are ...
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results